Home - Abcuro

Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease

news

Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual Meeting

March 11, 2025

Newton, Massachusetts, March 11, 2025 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that the Company will present safety, pharmacokinetic, and pharmacodynamic data from the Phase 1 clinical trial evaluating ulviprubart (ABC008) for the treatment of inclusion

March 11, 2025

Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual MeetingPress Releases

Targeting Highly Cytotoxic T Cells

Highly cytotoxic T cells have been implicated as mediators of tissue damage in many autoimmune diseases

ABC008 in Autoimmune Disorders

ABC008, an investigational monoclonal antibody, selectively depletes highly cytotoxic T cells

Inclusion Body Myositis

Inclusion body myositis (IBM) is a debilitating chronic, progressive disorder in which muscle is destroyed by highly cytotoxic T cells